Literature DB >> 7636236

Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells.

J F Rowell1, A L Ruff, F G Guarnieri, K Staveley-O'Carroll, X Lin, J Tang, J T August, R F Siliciano.   

Abstract

A subset of endogenously synthesized Ags can be processed for class II-restricted presentation, probably through multiple mechanisms. Processing of exogenous Ags for class II-restricted presentation appears to occur in unique endosomal processing compartments with lysosomal characteristics including the presence of the lysosomal membrane protein LAMP-1. Therefore, we attempted to enhance the efficiency of class II-restricted presentation of an endogenous Ag, the HIV-1 envelope (env) protein, by specifically targeting the Ag to class II processing compartments through the pathway followed by LAMP-1. Because the env protein associates tightly with CD4 shortly after synthesis, we first targeted the env protein using a chimeric CD4 protein consisting of the extracellular domain of CD4 and the transmembrane and cytoplasmic domains of LAMP-1. When co-expressed with this chimeric protein, the env protein was efficiently localized to lysosome-like compartments. Enhanced stimulation of env-specific CD4+ T cell clones by APC expressing the env protein and the CD4-LAMP-1 chimera was readily demonstrated in both cytotoxicity assays and proliferation assays. We also targeted the env protein directly as a chimeric protein consisting of the extracellular domain of the env protein and the transmembrane and cytoplasmic domains of LAMP-1. The proliferative response of env-specific CD4+ T cell clones to the env-LAMP-1 chimera was greatly enhanced compared with wild-type env protein, especially when limiting numbers of stimulator cells were used. The enhanced stimulatory capacity of APC expressing LAMP-1-targeted Ags has important implications for vaccine design.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.

Authors:  Lilit Aslanyan; Hiu H Lee; Vaibhav V Ekhar; Raddy L Ramos; Luis R Martinez
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

3.  cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails.

Authors:  E Olivetta; K Pugliese; R Bona; P D'Aloja; F Ferrantelli; A C Santarcangelo; G Mattia; P Verani; M Federico
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

Review 5.  Presentation of cytosolic antigens via MHC class II molecules.

Authors:  Delu Zhou; Janice S Blum
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef.

Authors:  Daniel G Kavanagh; Daniel E Kaufmann; Sherzana Sunderji; Nicole Frahm; Sylvie Le Gall; David Boczkowski; Eric S Rosenberg; David R Stone; Mary N Johnston; Bradford S Wagner; Mohammad T Zaman; Christian Brander; Eli Gilboa; Bruce D Walker; Nina Bhardwaj
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

7.  Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Authors:  Junko Matsuzaki; Takemasa Tsuji; Immanuel Luescher; Lloyd J Old; Protul Shrikant; Sacha Gnjatic; Kunle Odunsi
Journal:  Cancer Immunol Res       Date:  2013-12-17       Impact factor: 11.151

Review 8.  Protein sorting within the MHC class II antigen-processing pathway.

Authors:  M S Marks
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

9.  Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes.

Authors:  Antonio Valentin; Priya Chikhlikar; Vainav Patel; Margherita Rosati; Milton Maciel; Kern-Hee Chang; Peter Silvera; Barbara K Felber; George N Pavlakis; J Thomas August; Ernesto T A Marques
Journal:  Vaccine       Date:  2009-06-17       Impact factor: 3.641

10.  Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice.

Authors:  Gregory G Simon; Yongli Hu; Asif M Khan; Jingshi Zhou; Jerome Salmon; Priya R Chikhlikar; Keun-Ok Jung; Ernesto T A Marques; J Thomas August
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.